{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=38", "query": { "condition": "Non-Hodgkin's Lymphoma (disorder)", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 2150, "total_pages": 215, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T12:11:22.725Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02175433", "title": "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Lymphoid Malignancy", "Refractory Lymphoid Malignancy" ], "interventions": [ { "name": "AGS67E", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2014-10-14", "completion_date": "2019-10-29", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 4, "location_summary": "Duarte, California • Stanford, California • Fairway, Kansas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02175433" }, { "nct_id": "NCT00060255", "title": "High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Testicular Germ Cell Tumor", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 451, "start_date": "1991-12", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2013-05-09", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060255" }, { "nct_id": "NCT00386217", "title": "Psychosocial Impact of Cancer-Related Female Infertility", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hodgkin's Disease", "Cervical Cancer", "Breast Cancer", "Lymphoma" ], "interventions": [ { "name": "Telephone Survey", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "FEMALE", "summary": "14 Years and older · Female only" }, "enrollment_count": 239, "start_date": "2004-12", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386217" }, { "nct_id": "NCT01534078", "title": "Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Adriamycin, vinblastine, and dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2012-03", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2018-02-20", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 4, "location_summary": "Tampa, Florida • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534078" }, { "nct_id": "NCT04068597", "title": "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Haematological Malignancy", "Acute Myeloid Leukemia", "Non Hodgkin Lymphoma", "Multiple Myeloma", "Higher-risk Myelodysplastic Syndrome", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "CCS1477", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elranatamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2019-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068597" }, { "nct_id": "NCT00182650", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 5, "start_date": "2004-06", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2009-12-29", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00182650" }, { "nct_id": "NCT04978779", "title": "A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Richter Syndrome", "MYC Amplification", "MYC Overexpression", "MYC Translocation" ], "interventions": [ { "name": "VIP152", "type": "DRUG" }, { "name": "BTKi", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-12-16", "completion_date": "2023-05-26", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 4, "location_summary": "Cincinnati, Ohio • Columbus, Ohio • Dallas, Texas + 1 more", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978779" }, { "nct_id": "NCT01593696", "title": "Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALL", "B Cell Lymphoma", "Leukemia", "Large Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 53, "start_date": "2012-06-29", "completion_date": "2017-10-02", "has_results": true, "last_update_posted_date": "2020-08-31", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593696" }, { "nct_id": "NCT02071888", "title": "Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma (NHL)", "Multiple Myeloma", "Waldenstrom's Macroglobulinemia (WM)", "Other B-cell NHL Subtypes, Including WM", "T-cell NHL" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "CB-839 and low dose dexamethasone", "type": "DRUG" }, { "name": "CB-839, pomalidomide, and low dose dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-02", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071888" }, { "nct_id": "NCT03320642", "title": "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Calcineurin inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2018-02-27", "completion_date": "2022-02-17", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-17T12:11:22.725Z", "location_count": 9, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03320642" } ] }